Upregulated expression of leukocyte immunoglobulin‑like receptor A3 in patients with severe aplastic anemia

Yu,Hong; Liu,Hui; Zhao,Yang; Wang,Huaquan; Liu,Chunyan; Qi,Weiwei; Liu,Zhaoyun; Sun,Yingying; Gao,Shan; Tao,Jinglian; Fu,Rong; Shao,Zonghong

doi:10.3892/etm.2021.9777

Upregulated expression of leukocyte immunoglobulin‑like receptor A3 in patients with severe aplastic anemia

Authors:
- Hong Yu
- Hui Liu
- Yang Zhao
- Huaquan Wang
- Chunyan Liu
- Weiwei Qi
- Zhaoyun Liu
- Yingying Sun
- Shan Gao
- Jinglian Tao
- Rong Fu
- Zonghong Shao
View Affiliations

Affiliations: Department of Hematology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: February 11, 2021 https://doi.org/10.3892/etm.2021.9777
Article Number: 346
Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Severe aplastic anemia (SAA) is a rare and potentially life‑threatening disease characterized by pancytopenia and bone marrow (BM) hypoplasia. In a previous study by our group, increased expression of leukocyte immunoglobulin‑like receptors A (LILRA), LILRA3 in myeloid dendritic cells (mDCs) and LILRA5 in CD34⁺ cells in SAA was detected using proteomics techniques, highlighting their potential role in disease pathogenesis. In the present study, the expression of LILRA1‑6 mRNA was assessed in the BM mononuclear cells of patients with SAA using reverse transcription‑quantitative (RT‑q)PCR. The expression of homogenic LILRA3 and LILRA5 isoform on mDCs, as well as CD34⁺, CD3⁺CD8⁺, CD19⁺ and CD14⁺ cells, was detected using flow cytometry. mDCs were then induced, cultured and sorted. The expression of LILRA3 was confirmed using RT‑qPCR and western blot analyses. The serum levels of soluble LILRA3 were measured using ELISA. Furthermore, the relationship between LILRA3 expression and disease severity was assessed. The results indicated increased LILRA3 mRNA expression in patients with SAA. The percentage of LILRA3⁺ in BM mDCs and CD34⁺ cells was increased. Compared with controls, the relative LILRA3 mRNA expression and the relative protein intensity were highly increased in SAA mDCs. The serum LILRA3 levels in patients with SAA were also increased. The proportion of LILRA3⁺CD11C⁺ human leukocyte antigen (HLA)‑DR⁺/CD11C⁺HLA‑DR⁺ cells was positively correlated with the ratio of LILRA3⁺CD34⁺/CD34⁺ cells and the expression of LILRA3 mRNA. Taken together, the expression of LILRA3 on mDCs of patients with SAA was increased, which may affect the function of mDCs. LILRA3 may have a significant role in the immune pathogenesis of SAA.

View Figures

View References

1	Young NS: Aplastic anemia. N Engl J Med. 379:1643–1656. 2018.PubMed/NCBI View Article : Google Scholar
2	Young NS: The etiology of acquired aplastic anemia. Rev Clin Exp Hematol. 4:236–259. 2000.
3	Miano M and Dufour C: The diagnosis and treatment of aplastic anemia: A review. Int J Hematol. 101:527–535. 2015.PubMed/NCBI View Article : Google Scholar
4	Zeng Y and Katsanis E: The complex pathophysiology of acquired aplastic anaemia. Clin Exp Immunol. 180:361–370. 2015.PubMed/NCBI View Article : Google Scholar
5	Zonghong S, Meifeng T, Huaquan W, Limin X, Jun W, Rong F, Hong L and Yuhong W: Circulating myeloid dendritic cells are increased in individuals with severe aplastic anemia. Int J Hematol. 93:156–162. 2011.PubMed/NCBI View Article : Google Scholar
6	Liu C, Sheng W, Fu R, Wang H, Li L, Liu H and Shao Z: Differential expression of the proteome of myeloid dendritic cells in severe aplastic anemia. Cell Immunol. 285:141–148. 2013.PubMed/NCBI View Article : Google Scholar
7	Qi W, Fu R, Wang H, Liu C, Ren Y, Shao Y and Shao Z: Comparative proteomic analysis of CD34(+) cells in bone marrow between severe aplastic anemia and normal control. Cell Immunol. 304-305:9–15. 2016.PubMed/NCBI View Article : Google Scholar
8	Norman PJ, Carey BS, Stephens HAF and Vaughan RW: DNA sequence variation and molecular genotyping of natural killer leukocyte immunoglobulin-like receptor, LILRA3. Immunogenetics. 55:165–171. 2003.PubMed/NCBI View Article : Google Scholar
9	Brown D, Trowsdale J and Allen R: The LILR family: Modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens. 64:215–225. 2004.PubMed/NCBI View Article : Google Scholar
10	Hirayasu K and Arase H: Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet. 60:703–708. 2015.PubMed/NCBI View Article : Google Scholar
11	Jones DC, Kosmoliaptsis V, Apps R, Lapaque N, Smith I, Kono A, Chang C, Boyle LH, Taylor CJ, Trowsdale J and Allen RL: HLA class I allelic sequence and conformation regulate leukocyte Ig-like receptor binding. J Immunol. 186:2990–2997. 2011.PubMed/NCBI View Article : Google Scholar
12	An H, Lim C, Guillemin GJ, Vollmer-Conna U, Rawlinson W, Bryant K and Tedla N: Serum leukocyte immunoglobulin-like receptor A3 (LILRA3) is increased in patients with multiple sclerosis and is a strong independent indicator of disease severity; 6.7kbp LILRA3 gene deletion is not associated with diseases susceptibility. PLoS One. 11(e0149200)2016.PubMed/NCBI View Article : Google Scholar
13	Low HZ, Ahrenstorf G, Pommerenke C, Habermann N, Schughart K, Ordóñez D, Stripecke R, Wilk E and Witte T: TLR8 regulation of LILRA3 in monocytes is abrogated in human immunodeficiency virus infection and correlates to CD4 counts and virus loads. Retrovirology. 13(15)2016.PubMed/NCBI View Article : Google Scholar
14	Sugahara-Tobinai A, Inui M, Metoki T, Watanabe Y, Onuma R, Takai T and Kumaki S: Augmented ILT3/LILRB4 expression of peripheral blood antibody secreting cells in the acute phase of kawasaki disease. Pediatr Infect Dis J. 38:431–438. 2019.PubMed/NCBI View Article : Google Scholar
15	Debebe BJ, Boelen L and Lee JC: IAVI Protocol C Investigators. Sanders EJ, Anzala O, Kamali A, Kaleebu P, Karita E, Kilembe W, et al: Identifying the immune interactions underlying HLA class I disease associations. Elife. 9(e54558)2020.PubMed/NCBI View Article : Google Scholar
16	Camitta BM, Storb R and Thomas ED: Aplastic anemia (second of two parts): Pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 306:712–718. 1982.PubMed/NCBI View Article : Google Scholar
17	Camitta BM, Storb R and Thomas ED: Aplastic anemia (first of two parts): Pathogenesis, diagnosis, treatment, and prognosis. N Engl J Med. 306:645–652. 1982.PubMed/NCBI View Article : Google Scholar
18	Di Bona E, Rodeghiero F, Bruno B, Gabbas A, Foa P, Locasciulli A, Rosanelli C, Camba L, Saracco P, Lippi A, et al: Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anaemia patients unresponsive to a first course of intensive immunosuppressive therapy. Gruppo italiano trapianto di midollo osseo (GITMO). Br J Haematol. 107:330–334. 1999.PubMed/NCBI View Article : Google Scholar
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Method. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
20	Liu C and Shao Z: Aplastic anemia in China. J Transl Int Med. 6:134–137. 2018.PubMed/NCBI View Article : Google Scholar
21	Liu C, Sun Y and Shao Z: Current concepts of the pathogenesis of aplastic anemia. Curr Pharm Des. 25:236–241. 2019.PubMed/NCBI View Article : Google Scholar
22	Chen T, Zhang T, Liu C, Wang C, Ding S, Shao Z and Fu R: NK cells suppress CD8⁺ T cell immunity via NKG2D in severe aplastic anemia. Cell Immunol. 335:6–14. 2019.PubMed/NCBI View Article : Google Scholar
23	Liu B, Shao Y, Liu Z, Liu C, Zhang T and Fu R: Bone marrow plasma cytokine signature profiles in severe aplastic anemia. Biomed Res Int. 2020(8789275)2020.PubMed/NCBI View Article : Google Scholar
24	Liu C, Zheng M, Wang T, Jiang H, Fu R, Wang H, Ding K, Zhou Q and Shao Z: PKM2 is required to activate myeloid dendritic cells from patients with severe aplastic anemia. Oxid Med Cell Longev. 2018(1364165)2018.PubMed/NCBI View Article : Google Scholar
25	Steinbrink K, Mahnke K, Grabbe S, Enk AH and Jonuleit H: Myeloid dendritic cell: From sentinel of immunity to key player of peripheral tolerance. Hum Immunol. 70:289–293. 2009.PubMed/NCBI View Article : Google Scholar
26	Qi W, Yan L, Liu C, Fu R, Wang H and Shao Z: Abnormal histone acetylation of CD8⁺ T cells in patients with severe aplastic anemia. Int J Hematol. 104:540–547. 2016.PubMed/NCBI View Article : Google Scholar
27	Park JE, Brand DD, Rosloniec EF, Yi AK, Stuart JM, Kang AH and Myers LK: Leukocyte-associated immunoglobulin-like receptor 1 inhibits T-cell signaling by decreasing protein phosphorylation in the T-cell signaling pathway. J Biol Chem. 295:2239–2247. 2020.PubMed/NCBI View Article : Google Scholar
28	An H, Chandra V, Piraino B, Borges L, Geczy C, McNeil HP, Bryant K and Tedla N: Soluble LILRA3, a potential natural antiinflammatory protein, is increased in patients with rheumatoid arthritis and is tightly regulated by interleukin 10, tumor necrosis factor-alpha, and interferon-gamma. J Rheumatol. 37:1596–1606. 2010.PubMed/NCBI View Article : Google Scholar
29	Du Y, Sun F, Zhou M, Wu X, Sun W, Jiang Y, Cheng Q, Chen X, Wu H and Xue J: The expression and clinical significance of different forms of LILRA3 in systemic lupus erythematosus. Clin Rheumatol. 38:3099–3107. 2019.PubMed/NCBI View Article : Google Scholar
30	Low HZ, Reuter S, Topperwien M, Dankenbrink N, Peest D, Kabalak G, Stripecke R, Schmidt RE, Matthias T and Witte T: Association of the LILRA3 deletion with B-NHL and functional characterization of the immunostimulatory molecule. PLoS One. 8(e81360)2013.PubMed/NCBI View Article : Google Scholar
31	Nezos A, Evangelopoulos ME and Mavragani CP: Genetic contributors and soluble mediators in prediction of autoimmune comorbidity. J Autoimmun. 104(102317)2019.PubMed/NCBI View Article : Google Scholar